CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy

[1]  T. Mcclanahan,et al.  Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy , 2018, Clinical Cancer Research.

[2]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[3]  M. Bandehpour,et al.  Overview of CD24 as a new molecular marker in ovarian cancer , 2018, Journal of cellular physiology.

[4]  Franziska Michor,et al.  Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq , 2018, Nature Communications.

[5]  Mary Goldman,et al.  The UCSC Xena platform for public and private cancer genomics data visualization and interpretation , 2018, bioRxiv.

[6]  C. Abram,et al.  Shp1 function in myeloid cells , 2017, Journal of leukocyte biology.

[7]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[8]  D. Matei,et al.  Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. , 2017 .

[9]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[10]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  I. Weissman,et al.  Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential , 2015, PloS one.

[12]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[13]  Yang Liu,et al.  Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity. , 2014, Glycobiology.

[14]  S. Choi,et al.  Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. , 2014, Blood.

[15]  Xuetao Cao,et al.  Induction of Siglec-G by RNA Viruses Inhibits the Innate Immune Response by Promoting RIG-I Degradation , 2013, Cell.

[16]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[17]  F. Martínez.  Analysis of Gene Expression and Gene Silencing in Human Macrophages , 2012, Current protocols in immunology.

[18]  S. Kunkel,et al.  Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction , 2011, Nature Biotechnology.

[19]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[20]  Yang Liu,et al.  CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.

[21]  Ping Wang,et al.  A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. , 2009, Journal of immunological methods.

[22]  Ajit Varki,et al.  Siglecs and their roles in the immune system , 2007, Nature Reviews Immunology.

[23]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[24]  C. Pilarsky,et al.  CD24 expression is a new prognostic marker in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[26]  M. Colonna,et al.  Ig-Like Transcript 2 (ILT2)/Leukocyte Ig-Like Receptor 1 (LIR1) Inhibits TCR Signaling and Actin Cytoskeleton Reorganization1 , 2001, The Journal of Immunology.

[27]  T. Lebien,et al.  The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. , 1986, Journal of immunology.

[28]  I. Weissman,et al.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy , 2017, Nature Immunology.

[29]  Y. Luo,et al.  Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. , 1993, Blood.